CA Patent

CA3178691A1 — Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof

Assigned to Syndax Pharmaceuticals Inc · Expires 2021-10-14 · 5y expired

What this patent protects

The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.

USPTO Abstract

The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.

Drugs covered by this patent

Patent Metadata

Patent number
CA3178691A1
Jurisdiction
CA
Classification
—
Expires
2021-10-14
Drug substance claim
No
Drug product claim
No
Assignee
Syndax Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.